Published in J Biol Chem on June 17, 2002
Thrombin. Mol Aspects Med (2008) 1.80
The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood (2011) 1.71
Structural identification of the pathway of long-range communication in an allosteric enzyme. Proc Natl Acad Sci U S A (2008) 1.31
Conformational selection in trypsin-like proteases. Curr Opin Struct Biol (2012) 1.20
Crystal structure of wild-type human thrombin in the Na+-free state. Biochem J (2005) 1.18
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood (2007) 1.12
Engineering thrombin for selective specificity toward protein C and PAR1. J Biol Chem (2010) 1.09
Allostery in trypsin-like proteases suggests new therapeutic strategies. Trends Biotechnol (2011) 1.07
Thrombin-activatable procarboxypeptidase B regulates activated complement C5a in vivo. Blood (2006) 1.05
Mechanism of the anticoagulant activity of thrombin mutant W215A/E217A. J Biol Chem (2009) 0.95
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. Stroke (2011) 0.94
How Na+ activates thrombin--a review of the functional and structural data. Biol Chem (2008) 0.92
Stabilization of the E* form turns thrombin into an anticoagulant. J Biol Chem (2009) 0.91
Evidence of the E*-E equilibrium from rapid kinetics of Na+ binding to activated protein C and factor Xa. J Phys Chem B (2010) 0.89
Rigidification of the autolysis loop enhances Na(+) binding to thrombin. Biophys Chem (2011) 0.88
Redesigning allosteric activation in an enzyme. Proc Natl Acad Sci U S A (2011) 0.82
Thrombin mutant W215A/E217A treatment improves neurological outcome and attenuates central nervous system damage in experimental autoimmune encephalomyelitis. Metab Brain Dis (2014) 0.81
WEDGE: an anticoagulant thrombin mutant produced by autoactivation. J Thromb Haemost (2014) 0.77
Thrombomodulin is required for the antithrombotic activity of thrombin mutant W215A/E217A in a mouse model of arterial thrombosis. Thromb Res (2011) 0.77
Design of Factor XIII V34X activation peptides to control ability to interact with thrombin mutants. Biochim Biophys Acta (2011) 0.77
Interaction between thrombin mutant W215A/E217A and direct thrombin inhibitor. Blood Coagul Fibrinolysis (2008) 0.76
Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice. Blood (2016) 0.76
Rational Design of Protein C Activators. Sci Rep (2017) 0.75
Switching cation-binding loops paves the way for redesigning allosteric activation. Proc Natl Acad Sci U S A (2011) 0.75
Screening Cleavage of Factor XIII V34X Activation Peptides by Thrombin Mutants: A Strategy for Controlling Fibrin Architecture. Biochim Biophys Acta (2017) 0.75
Three dimensional optical angiography. Opt Express (2007) 8.30
Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci (2002) 1.96
Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood (2008) 1.89
A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood (2010) 1.83
Thrombin mutant W215A/E217A acts as a platelet GPIb antagonist. Arterioscler Thromb Vasc Biol (2007) 1.80
Role of Na+ and K+ in enzyme function. Physiol Rev (2006) 1.80
Molecular dissection of Na+ binding to thrombin. J Biol Chem (2004) 1.72
The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood (2011) 1.71
Studies on the basis for the properties of fibrin produced from fibrinogen-containing gamma' chains. Blood (2005) 1.64
Delayed inflammatory response to primary pneumonic plague occurs in both outbred and inbred mice. Infect Immun (2006) 1.59
Numerical investigation of the effects of channel geometry on platelet activation and blood damage. Ann Biomed Eng (2010) 1.58
Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem (2006) 1.58
Factor XI-dependence of surface- and tissue factor-initiated thrombus propagation in primates. Blood (2003) 1.55
Exposure of R169 controls protein C activation and autoactivation. Blood (2012) 1.52
Conformational selection or induced fit? A critical appraisal of the kinetic mechanism. Biochemistry (2012) 1.39
Structural identification of the pathway of long-range communication in an allosteric enzyme. Proc Natl Acad Sci U S A (2008) 1.31
Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler Thromb Vasc Biol (2013) 1.30
Rapid kinetics of Na+ binding to thrombin. J Biol Chem (2006) 1.29
Analysis of pulmonary inflammation and function in the mouse and baboon after exposure to Mycoplasma pneumoniae CARDS toxin. PLoS One (2009) 1.27
The effect of a recombinant elastin-mimetic coating of an ePTFE prosthesis on acute thrombogenicity in a baboon arteriovenous shunt. Biomaterials (2006) 1.24
Crystal structures of murine thrombin in complex with the extracellular fragments of murine protease-activated receptors PAR3 and PAR4. Proc Natl Acad Sci U S A (2007) 1.23
Conformational selection in trypsin-like proteases. Curr Opin Struct Biol (2012) 1.20
Evolution of peptidase diversity. J Biol Chem (2008) 1.16
Relative antithrombotic and antihemostatic effects of protein C activator versus low-molecular-weight heparin in primates. Blood (2007) 1.12
Crystal structure of thrombin in a self-inhibited conformation. J Biol Chem (2006) 1.11
The anticoagulant thrombin mutant W215A/E217A has a collapsed primary specificity pocket. J Biol Chem (2004) 1.10
Engineering thrombin for selective specificity toward protein C and PAR1. J Biol Chem (2010) 1.09
Thrombomodulin changes the molecular surface of interaction and the rate of complex formation between thrombin and protein C. J Biol Chem (2004) 1.08
Allostery in trypsin-like proteases suggests new therapeutic strategies. Trends Biotechnol (2011) 1.07
Glycosaminoglycan mimetic biomaterials. 4. Synthesis of sulfated lactose-based glycopolymers that exhibit anticoagulant activity. Biomacromolecules (2002) 1.06
The leech product saratin is a potent inhibitor of platelet integrin alpha2beta1 and von Willebrand factor binding to collagen. FEBS J (2007) 1.06
Redesigning the monovalent cation specificity of an enzyme. Proc Natl Acad Sci U S A (2003) 1.05
Quantitative characterization of developing collagen gels using optical coherence tomography. J Biomed Opt (2010) 1.05
Conformational selection is a dominant mechanism of ligand binding. Biochemistry (2013) 1.05
Capture of circulatory endothelial progenitor cells and accelerated re-endothelialization of a bio-engineered stent in human ex vivo shunt and rabbit denudation model. Eur Heart J (2011) 1.04
Mechanism of Na(+) binding to thrombin resolved by ultra-rapid kinetics. Biophys Chem (2007) 1.01
Endothelial cell cytoskeletal alignment independent of fluid shear stress on micropatterned surfaces. Biochem Biophys Res Commun (2008) 1.01
Non-destructive label-free monitoring of collagen gel remodeling using optical coherence tomography. Biomaterials (2010) 0.99
Crystal structure of thrombin in complex with fibrinogen gamma' peptide. Biophys Chem (2006) 0.99
Crystallographic and kinetic evidence of allostery in a trypsin-like protease. Biochemistry (2011) 0.98
Thrombin formation in vitro in response to shear-induced activation of platelets. Thromb Res (2007) 0.98
Mutant N143P reveals how Na+ activates thrombin. J Biol Chem (2009) 0.97
Potential of baboon endothelial progenitor cells for tissue engineered vascular grafts. J Biomed Mater Res A (2008) 0.97
Crystal structures of prethrombin-2 reveal alternative conformations under identical solution conditions and the mechanism of zymogen activation. Biochemistry (2011) 0.97
Important role of the cys-191 cys-220 disulfide bond in thrombin function and allostery. J Biol Chem (2007) 0.96
Crystal structure of thrombin bound to the uncleaved extracellular fragment of PAR1. J Biol Chem (2010) 0.96
Crystal structure of the anticoagulant slow form of thrombin. J Biol Chem (2002) 0.96
A novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase: molecular mechanisms and anti-inflammatory activity in vivo. J Biol Chem (2005) 0.96
Crystal structure of prethrombin-1. Proc Natl Acad Sci U S A (2010) 0.96
Fibrinogen gamma' chain carboxy terminal peptide selectively inhibits the intrinsic coagulation pathway. Br J Haematol (2007) 0.96
Dissecting substrate recognition by thrombin using the inactive mutant S195A. Biophys Chem (2003) 0.96
Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis. J Infect Dis (2008) 0.95
Mechanism of the anticoagulant activity of thrombin mutant W215A/E217A. J Biol Chem (2009) 0.95
Flow and thrombosis at orifices simulating mechanical heart valve leakage regions. J Biomech Eng (2006) 0.95
Energetic and structural consequences of perturbing Gly-193 in the oxyanion hole of serine proteases. J Biol Chem (2005) 0.95
An age-old paradigm challenged: old baboons generate vigorous humoral immune responses to LcrV, a plague antigen. J Immunol (2008) 0.95
Thrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke. Stroke (2011) 0.94
Fluid shear stress alters the hemostatic properties of endothelial outgrowth cells. Tissue Eng Part A (2011) 0.93
Murine thrombin lacks Na+ activation but retains high catalytic activity. J Biol Chem (2006) 0.93
The conformation of the activation peptide of protein C is influenced by Ca2+ and Na+ binding. J Biol Chem (2004) 0.93
Crystal structure of prothrombin reveals conformational flexibility and mechanism of activation. J Biol Chem (2013) 0.92
Ser(214) is crucial for substrate binding to serine proteases. J Biol Chem (2002) 0.92
Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem (2007) 0.92
Three-dimensional models of proteases involved in patterning of the Drosophila Embryo. Crucial role of predicted cation binding sites. J Biol Chem (2002) 0.92
Autoactivation of thrombin precursors. J Biol Chem (2013) 0.92
Procoagulant properties of flow fields in stenotic and expansive orifices. Ann Biomed Eng (2007) 0.91
Stabilization of the E* form turns thrombin into an anticoagulant. J Biol Chem (2009) 0.91
The thrombin epitope recognizing thrombomodulin is a highly cooperative hot spot in exosite I. J Biol Chem (2002) 0.90
Residue Asp-189 controls both substrate binding and the monovalent cation specificity of thrombin. J Biol Chem (2003) 0.89
Evidence of the E*-E equilibrium from rapid kinetics of Na+ binding to activated protein C and factor Xa. J Phys Chem B (2010) 0.89
Small-caliber heparin-coated ePTFE grafts reduce platelet deposition and neointimal hyperplasia in a baboon model. J Vasc Surg (2004) 0.89
Cytoskeletal structure regulates endothelial cell immunogenicity independent of fluid shear stress. Am J Physiol Cell Physiol (2009) 0.89
Hirudin binding reveals key determinants of thrombin allostery. J Biol Chem (2005) 0.88
High resolution crystal structures of free thrombin in the presence of K(+) reveal the molecular basis of monovalent cation selectivity and an inactive slow form. Biophys Chem (2006) 0.88
Distinct extracellular matrix microenvironments of progenitor and carotid endothelial cells. J Biomed Mater Res A (2009) 0.88
Rigidification of the autolysis loop enhances Na(+) binding to thrombin. Biophys Chem (2011) 0.88
Thrombin functions through its RGD sequence in a non-canonical conformation. J Biol Chem (2005) 0.86
Conserved Ser residues, the shutter region, and speciation in serpin evolution. J Biol Chem (2003) 0.86
Histone H4 promotes prothrombin autoactivation. J Biol Chem (2013) 0.86
Capture of flowing endothelial cells using surface-immobilized anti-kinase insert domain receptor antibody. Tissue Eng Part C Methods (2008) 0.85
Substrate recognition drives the evolution of serine proteases. J Biol Chem (2002) 0.85
Structural basis of Na+ activation mimicry in murine thrombin. J Biol Chem (2007) 0.85
A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo. J Biol Chem (2005) 0.85
Soluble thrombomodulin is antithrombotic in the presence of neutralising antibodies to protein C and reduces circulating activated protein C levels in primates. Br J Haematol (2006) 0.84
Structural basis of thrombin-protease-activated receptor interactions. IUBMB Life (2011) 0.84
Three-dimensional modeling of thrombin-fibrinogen interaction. J Biol Chem (2002) 0.83
Engineering protein allostery: 1.05 A resolution structure and enzymatic properties of a Na+-activated trypsin. J Mol Biol (2008) 0.83
Factor VIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model. Bioorg Med Chem Lett (2006) 0.82
Redesigning allosteric activation in an enzyme. Proc Natl Acad Sci U S A (2011) 0.82
Conversion of trypsin into a Na(+)-activated enzyme. Biochemistry (2006) 0.82
Engineering protease specificity made simple, but not simpler. Nat Chem Biol (2008) 0.82
Thrombotic responses of endothelial outgrowth cells to protein-coated surfaces. Cells Tissues Organs (2015) 0.82